Section 5: Patient Safety and Quality Assurance

5PSQ-032

ADMINISTRATION PROTOCOL FOR PENICILLIN G IN A PATIENT WITH A SEVERE REACTION TO BETALACTAMS AND ABDOMINAL ACTINOMYCOSIS

5PSQ-031

A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS

5PSQ-030

DO WE KNOW WHICH ANTIBIOTICS SHOULD BE AVOIDED IN OUR PATIENTS? ANTIBIOTIC ALLERGY SURVEY AMONG HOSPITALISED PATIENTS

5PSQ-029

EFFECTIVENESS AND SAFETY OF EVOLOCUMAB IN REAL CLINICAL PRACTICE

5PSQ-028

THE GOVERNANCE OF PCSK9-INHIBITORS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA: APPROPRIATENESS ANALYSIS

5PSQ-027

EFFECTIVENESS AND SAFETY OF TOLVAPTAN AND UREA FOR THE TREATMENT OF SEVERE SYMPTOMATIC HYPONATRAEMIA: A CASE SERIES

5PSQ-026

IMPACT OF A SAFETY ALERT WITH VALSARTAN IN A HEALTH MANAGEMENT AREA

5PSQ-025

PULMONARY ARTERIAL HYPERTENSION DRUGS: EPIDEMIOLOGICAL ANALYSIS CONCERNING AN ITALIAN DISTRICT

5PSQ-024

MEDICATION ERRORS - A CAUSE FOR MAJOR CARDIOVASCULAR EVENTS IN AN EMERGENCY DEPARTMENT

5PSQ-023

ADEQUATE DIGOXIN DOSAGE IN PATIENTS WITH DIGITALIS TOXICITY

5PSQ-022

AN EVALUATION OF THE PHARMACIST INTERVENTION IN INTRAVENOUS MIXTURES' STABILITY

5PSQ-021

PHARMACOGENETIC TESTING FOR PERSONALISATION OF STATIN THERAPY

5PSQ-020

SAFETY EVALUATION OF INJECTABLE POTASSIUM CHLORIDE PRESCRIPTIONS IN HOSPITAL

5PSQ-019

SWITCHING FROM INDIVIDUALISED NUTRITION TO STANDARDISED OR COMMERCIALISED NUTRITION IN NEWBORNS: ARE THERE ANY POSSIBILITIES?

5PSQ-018

IMPLEMENTATION OF PARENTERAL NUTRITION PRESCRIBING SOFTWARE IN A NEONATAL INTENSIVE CARE UNIT

Pages